Crystal S. Denlinger, MD, FACP

Dr. Crystal Denlinger
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Clinical Locations

Adjunct Professor, Department of Hematology/Oncology

Clinical Associate Professor (Adjunct), Department of Medicine-Oncology, Lewis Katz School of Medicine, Temple University

Treatment Focus

Gastroesophageal cancers (esophagus, GE junction, and stomach cancers); liver, gall bladder & bile duct cancer; Cancer Survivorship

Research Program

Key Awards

2023 top doctors
Medical Oncology

National Comprehensive Cancer Center Foundation Young Investigator Award, 2012-2014

Treatment Philosophy

Each patient is unique, with different goals and wishes for their lives and individual cases of cancer.  As a medical oncologist, I strive to ensure the best possible treatment for my patients.  As a gastrointestinal cancer specialist, I work in a multidisciplinary fashion with my colleagues in surgery, radiation oncology, and gastroenterology to provide a holistic approach to the patient and his or her cancer. This may include standard treatment options or experimental therapies on a clinical trial, reflective of my interest in developing new and more effective therapies for gastrointestinal cancers.  I work with patients to identify their goals and tailor treatment to meet all of their needs.  In addition, I work to ensure a high level of quality of life during treatment.  This is reflective of my interest in cancer survivorship, which addresses the effects of cancer and its treatment on the individual and their lives and families. 

Facing a diagnosis of cancer is a daunting and difficult challenge.  I believe it is my responsibility to make that diagnosis easier to understand and provide guidance as to how to meet that challenge head-on.  Once the journey has begun, my role is to ensure that each patient has the best tools to face their disease, in keeping with their goals for treatment.  At the end of the road, my role is to help each patient transition to the end of their life in keeping with their wishes.  In each of these stages, I strive to work with patients and families to provide the best and most comprehensive care to meet their needs.

Educational Background

  • Fellow, Hematology/Oncology, Fox Chase Cancer Center/Temple University Hospital, Philadelphia, PA
  • Resident, Internal Medicine, Mount Sinai Medical Center, New York, NY
  • MD, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ


  • Diplomate, Medical Oncology, American Board of Internal Medicine, 2007
  • Diplomate, Internal Medicine, American Board of Internal Medicine, 2004, 2014 


  • National Comprehensive Cancer Network (NCCN)
    • Esophageal/Gastric Cancers Panel
    • JNCCN Editorial Board
    • Survivorship Panel
    • Survivorship Panel: Anxiety and Depression
    • Survivorship Panel: Cardiac Toxicity
    • Survivorship Panel: Menopause
    • Survivorship Panel: Physical Activity/Nutrition/Weight Management (Healthy Lifestyles)
  • Academic GI Cancer Consortium
  • American College of Physicians
  • American Society of Clinical Oncology
  • Eastern Cooperative Oncology Group, Gastrointestinal Cancer Committee
  • National Comprehensive Cancer Network, Chair, National Comprehensive Cancer Network Cancer Survivorship Panel; Gastric Cancer Panel, Chemotherapy Subcommittee Member, Genetics Subcommittee Member; Esophageal Cancer Panel, Chemotherapy Subcommittee Member, Genetics Subcommittee Member
  • Sigma Xi Scientific Research Society, Associate Member

Honors & Awards

  • Special Contributor Award, Fox Chase Cancer Center, 2014
  • CHASE Award, Fox Chase Cancer Center Annual Cancer Survivors Celebration, 2011
  • Participant, ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, CO, 2008
  • ASCO Foundation Merit Award, ASCO Gastrointestinal Cancers Symposium, Orlando, FL, 2007

Sterling Randolph

  • Colorectal Cancer

Sitting in my car on the side of the road, it was like time had stopped. All I could think about was my family. What would they do without me?


Research Interests

Gastrointestinal cancers; Cancer Survivorship; Drug Development

Selected Publications

He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, Giles J, Wallin J, Moser B, Zhang W, Walgren R, Plimack ER. First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. The oncologist, 2019.

 Upshaw JN, O'Neill A, Carver JR, Dimond EP, Denlinger CS, Kircher SM, Wagner LI, Ky B, Brell JM. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. Clinical Colorectal Cancer, 18(1):44-51, 2019. PubMed

Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O’Dwyer PJ.  Pharmacokinetic and pharmacogenetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.  Cancer Chemotherapy and Pharmocology, Dec;65(1):97-105, 2009. Epub 2009 May 5. PMID: 2746259, NIHMS 110194. PubMed

Denlinger CS, Barsevick AM.  The challenges of colorectal cancer survivorship.  Journal of the National Comprehensive Cancer Network, 7(8):  883-894, 2009.  PMID: 19755048. PubMed

Denlinger CS, Engstrom PF. Colorectal cancer survivorship: movement matters. Cancer Prevention Research, 4(4):502-11, Apr, 2011.  Epub April 3, 2011.  PMID: 21464030. PubMed

Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the Management of Older Patients With Colon Cancer. Journal of the National Comprehensive Cancer Network,  10(2): p. 213-224, 2012. PMID:  22308516. PubMed

Ligibel JA and Denlinger CS.  New NCCN Guidelines(R) for survivorship care.  Journal of the National Comprehensive Cancer Network, 11(5 Suppl):  640-644, 2013. PubMed

Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.  A phase II trial of bortezomib in patients with advanced biliary tract cancers.  Clinical Colorectal Cancer 13(2):  81-86, 2014  .Epub ahead of print Jan 4 2014.  PMID 24512954. PubMed

Denlinger CS and Ligibel J.  A Work In Progress:  Developing the new NCCN Survivorship Guidelines.  Journal of the National Comprehensive Cancer Network, 12(1):  1-4, 2014.  PMID:  24453287. PubMed

Dotan E, Devarajan K, D’Silva AJ, Beck A, Kloth DD, Cohen SJ, Denlinger C.  Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.  Clinical Colorectal Cancer 2014 Sept; 13(3):  192-198. Epub ahead of print Jun 26 2014.  PMID:  25074246. PubMed

Morgan MA, Denlinger CS.  Survivorship: tools for transitioning patients with cancer. Journal of the National Comprehensive Cancer Network. 2014 Dec;12(12):1681-1687.  PMID:25505209.  PubMed

Shah M and Denlinger CS.  Optimal post-treatment surveillance in cancer survivors:  is more really better?  Oncology 2015 29(4):  230-240. PMID: 25952485. PubMed

Vijayvergia N and Denlinger CS. Lifestyle factors in Cancer Survivorship: Where we are and where we are headed.  Journal of Personalized Medicine. 2015 5(3): 243-263. PubMed

Vijayvergia N, Shah PC, Denlinger CS.  Survivorship in non-small cell lung cancer:  challenges faced and steps forward.  Journal of the National Comprehensive Cancer Network.  2015 Sep;13(9):1151-61. PMID: 26358799. PubMed

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...